Pharmaceutical preparation

Abstract

The present invention relates to a pharmaceutical preparation for treating an inflammatory condition, preferably a condition associated with ischemia comprising: a) a physiological solution comprising peripheral blood mononuclear cells (PBM-Cs) or a subset thereof, or b) a supernatant of the solution a), wherein the solution a) is obtainable by cultivating PBMCs or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.

1 - 16 . (canceled) 
     
     
         17 . A method of treating an inflammatory condition, comprising:
 administering a pharmaceutical preparation comprising a cell-free culture supernatant of peripheral blood mononuclear cells (PBMCs) to a patient in need of treatment for an inflammatory condition selected from the group consisting of myocardial ischemia, limb ischemia, tissue ischemia, ischemia-reperfusion injury, angina pectoris, coronary artery disease, peripheral vascular disease, peripheral arterial disease, stroke, ischemic stroke, myocardial infarct, congestive heart failure, trauma, bowel disease, mesenterial infarction, pulmonary infarction, bone fracture, tissue regeneration after dental grafting, auto-immune diseases, rheumatic diseases, transplantation allograft and rejection of allograft,   the PBMCs comprising non-activated, non-proliferating T cells, B cells, NK cells, and monocytes cultivated under a stress inducing condition in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.   
     
     
         18 . The method of  claim 17 , wherein the cell-free culture supernatant comprises at least 2000 pg/mL of matrix metallopeptidase 9 (MMP-9) and no detectable amount of TNF-α. 
     
     
         19 . The method of  claim 17 , wherein the cell-free culture supernatant has no detectable amount of INF-γ. 
     
     
         20 . The method of  claim 17 , wherein the stress inducing condition comprises a dose of γ-radiation. 
     
     
         21 . The method of  claim 20 , wherein the dose of γ-radiation is at least 10 Gy. 
     
     
         22 . The method of  claim 20 , wherein the dose of γ-radiation is at least 20 Gy. 
     
     
         23 . The method of  claim 20 , wherein the dose of γ-radiation is at least 40 Gy. 
     
     
         24 . The method of  claim 17 , wherein the pharmaceutical preparation is administered by subcutaneous administration, intramuscular administration, intra-organ administration, or intravenous administration. 
     
     
         25 . The method of  claim 17 , wherein the physiological solution is selected from the group consisting of a salt solution, whole blood, blood fraction, and a cell culture medium. 
     
     
         26 . The method of  claim 23 , wherein the salt solution is a physiological NaCl solution. 
     
     
         27 . The method of  claim 17 , wherein the blood fraction is serum. 
     
     
         28 . The method of  claim 17 , wherein the PBMCs are cultivated in the physiological solution for at least 4 hours. 
     
     
         29 . The method of  claim 17 , wherein the PBMCs are cultivated in the physiological solution for at least 12 hours. 
     
     
         30 . The method of  claim 17 , wherein the culture supernatant comprises PBMCs. 
     
     
         31 . A method of treating an inflammatory condition, comprising:
 administering a pharmaceutical preparation comprising a cell-free culture supernatant of peripheral blood mononuclear cells (PBMCs) to a patient in need of treatment for an inflammatory condition selected from the group consisting of myocardial ischemia, myocardial infarct, and congestive heart failure,   the PBMCs comprising non-activated, non-proliferating T cells, B cells, NK cells, and monocytes cultivated under a stress inducing condition in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.   
     
     
         32 . The method of  claim 31 , wherein the cell-free culture supernatant comprises at least 2000 pg/mL of matrix metallopeptidase 9 (MMP-9), no detectable amount of TNF-α, and no detectable amount of INF-γ. 
     
     
         33 . The method of  claim 31 , wherein the stress inducing condition comprises a dose of at least 10 Gy radiation. 
     
     
         34 . The method of  claim 31 , wherein the pharmaceutical preparation is administered by intra-organ administration or intravenous administration. 
     
     
         35 . A method of treating an inflammatory condition, comprising:
 administering a pharmaceutical preparation comprising a cell-free culture supernatant of peripheral blood mononuclear cells (PBMCs) to a patient in need of treatment for an inflammatory condition selected from the group consisting of myocardial ischemia, myocardial infarct, and congestive heart failure,   the cell-free culture supernatant comprising at least 2000 pg/mL of matrix metallopeptidase 9 (MMP-9) and no detectable amount of TNF-α,   the PBMCs comprising non-activated, non-proliferating T cells, B cells, NK cells, and monocytes cultivated under a stress inducing condition comprising a dose of at least 10 Gy radiation in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.   
     
     
         36 . The method of  claim 35 , wherein the pharmaceutical preparation is administered by intra-organ administration or intravenous administration.